BRCA1 and breast cancer: For example, PI3K inhibitors have synergistic therapeutic effects if associated with PARPi in BRCA1-deficient breast cancer models, with the PI3K/AKT pathway being constitutively active in BRCA1-defective human cancer cells [110,111].